Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis.
Fatty liver disease
NAFLD
NASH
fibrosis
therapeutics
Journal
TouchREVIEWS in endocrinology
ISSN: 2752-5457
Titre abrégé: touchREV Endocrinol
Pays: England
ID NLM: 101779126
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
10
03
2022
accepted:
19
08
2022
entrez:
25
1
2023
pubmed:
26
1
2023
medline:
26
1
2023
Statut:
ppublish
Résumé
Non-alcoholic steatohepatitis (NASH) now represents one of the most prevalent forms of cirrhosis and hepatocellular carcinoma. A number of treatment agents have undergone assessment in humans following promising results in animal models. Currently, about 50 therapeutic agents are in various stages of development. Recently, however, there have been a number of exciting and positive developments in this landscape, although there are inherent challenges ahead. In this article, we review the aetiological and pathological basis of NASH progression and describe putative targets for current therapies. We also discuss some of the likely future directions and difficulties around this complex and challenging disease paradigm.
Identifiants
pubmed: 36694893
doi: 10.17925/EE.2022.18.2.148
pmc: PMC9835815
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
148-155Informations de copyright
© Touch Medical Media 2022.
Références
QJM. 2010 Feb;103(2):71-83
pubmed: 19914930
Ann Intern Med. 2016 Sep 6;165(5):305-15
pubmed: 27322798
Thyroid. 2019 Sep;29(9):1173-1191
pubmed: 31389309
JHEP Rep. 2020 Jul 21;2(5):100148
pubmed: 32954243
Lancet. 2019 Nov 30;394(10213):2012-2024
pubmed: 31727409
Eur J Intern Med. 2021 Jul;89:56-64
pubmed: 33867228
JACC Cardiovasc Imaging. 2013 Nov;6(11):1172-82
pubmed: 24229770
Clin Gastroenterol Hepatol. 2021 Nov;19(11):2274-2283.e5
pubmed: 32882428
J Med Chem. 2018 Mar 22;61(6):2246-2265
pubmed: 29446942
Gastroenterology. 2019 Apr;156(5):1264-1281.e4
pubmed: 30660725
Curr Hepatol Rep. 2017;16(4):391-397
pubmed: 29984130
J Hepatol. 2022 Sep;77(3):607-618
pubmed: 35439567
Hepatology. 2021 Mar;73(3):881-883
pubmed: 33179266
Nat Med. 2021 Oct;27(10):1836-1848
pubmed: 34635855
Atherosclerosis. 2013 Oct;230(2):373-80
pubmed: 24075770
J Med Chem. 2014 May 22;57(10):3912-23
pubmed: 24712661
Nat Rev Gastroenterol Hepatol. 2021 Dec;18(12):835-856
pubmed: 34508238
Contemp Clin Trials. 2020 Nov;98:106170
pubmed: 33038502
Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):40-52
pubmed: 31641249
Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):24-39
pubmed: 33093663
J Hepatol. 2016 Feb;64(2):399-408
pubmed: 26394161
Lancet. 2019 Dec 14;394(10215):2184-2196
pubmed: 31813633
Cell. 1992 Mar 6;68(5):879-87
pubmed: 1312391
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2020 Sep;72(3):892-905
pubmed: 31943293
J Hepatol. 2022 May;76(5):1215-1224
pubmed: 35066087
Biol Pharm Bull. 2013;36(2):259-67
pubmed: 23370355
Gut. 2020 Sep;69(9):1691-1705
pubmed: 32321858
JHEP Rep. 2019 Jul 19;1(4):312-328
pubmed: 32039382
Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5
pubmed: 25865049
J Hepatol. 2021 Jul;75(1):12-15
pubmed: 33985820
JACC Basic Transl Sci. 2018 Nov 21;3(6):844-857
pubmed: 30623143
J Hepatol. 2009 Aug;51(2):380-8
pubmed: 19501927
J Hepatol. 2018 Feb;68(2):362-375
pubmed: 29122694
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266
pubmed: 31981519
N Engl J Med. 2010 May 6;362(18):1675-85
pubmed: 20427778
Annu Rev Nutr. 1997;17:77-99
pubmed: 9240920
N Engl J Med. 2021 Mar 25;384(12):1113-1124
pubmed: 33185364
J Med Chem. 2014 Dec 26;57(24):10512-26
pubmed: 25423286
Gastroenterology. 2014 Mar;146(3):726-35
pubmed: 24316260
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
Annu Rev Physiol. 2016;78:223-41
pubmed: 26654352
Lancet. 2016 Feb 13;387(10019):679-690
pubmed: 26608256
Endocrinology. 2014 Nov;155(11):4591-601
pubmed: 25121996
Nat Med. 2021 Oct;27(10):1825-1835
pubmed: 34621052
N Engl J Med. 2021 Oct 21;385(17):1547-1558
pubmed: 34670042
Biochim Biophys Acta. 2012 May;1821(5):809-18
pubmed: 22056763
Gastroenterology. 2021 Jan;160(1):219-231.e1
pubmed: 32781086
Lancet. 2021 Mar 13;397(10278):971-984
pubmed: 33667417
Hepatology. 2017 Aug;66(2):324-334
pubmed: 28470676
Aliment Pharmacol Ther. 2019 Nov;50(10):1100-1111
pubmed: 31583739
Lancet. 2019 Dec 22;392(10165):2705-2717
pubmed: 30554783
Liver Int. 2019 Nov;39(11):2082-2093
pubmed: 31402538
World J Hepatol. 2022 Jan 27;14(1):168-179
pubmed: 35126846
Biomed Rep. 2017 May;6(5):495-502
pubmed: 28515909
Sci Transl Med. 2019 Nov 27;11(520):
pubmed: 31776293
Obesity (Silver Spring). 2017 Jan;25(1):155-165
pubmed: 27804232
Gut. 2020 Oct;69(10):1877-1884
pubmed: 32381514
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Lipid Res. 2008 Nov;49(11):2283-301
pubmed: 18757836
Lancet. 2015 Mar 14;385(9972):956-65
pubmed: 25468160
Expert Opin Investig Drugs. 2020 Feb;29(2):135-141
pubmed: 31519114
Hepatol Commun. 2021 Jan 04;5(4):573-588
pubmed: 33860116